Shilpa Medicare gets Establishment Inspection Report from USFDA for Raichur facility
New Delhi: Shilpa Medicare said the US health regulator has issued an establishment inspection report (EIR) for its Raichur facility in Karnataka.
"We are in receipt of EIR (establishment inspection report) from the US Food and Drug Administration (USFDA) to our both API manufacturing facilities located at Raichur, Karnataka," Shilpa Medicare said in a BSE filing.
This inspection was carried out between January 16-19, 2018. The inspection has now been closed by the USFDA, it added.
USFDA gives EIR on the closure of inspection of an establishment that is the subject of an FDA or FDA-contracted inspection.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd